As Demy-Colton and EBD Group’s Biotech Showcase™ concluded its 18th year SAN FRANCISCO, CA, UNITED STATES, February 10, ...

Grogan served as assistant to President Trump and director of the Domestic Policy Council 2019-2020. On April 15, President Trump issued an awaited executive order on drug pricing, kicking off a new ...

T he biotech and pharmaceutical sectors stand at the brink of innovation and strategic transformation. Market momentum continues to build, with the global biotechnology market valued at around $2 ...

Arsenale Bioyards standardizes biomanufacturing from the industrial side, aiming to make biopharmaceutical manufacturing efficient, scalable, and cost-effective, much as the Bessemer converter did for ...

A group of European venture capital firms is banding together to try to improve the funding landscape for biotech startups.

The First Trust NYSE Arca Biotechnology ETF (FBT) was launched on June 19, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

Chinese pharmaceutical companies that as a group chalked up record outbound licensing agreements with international industry ...

George is a professor of genetics at Harvard Medical School and professor of health sciences and technology at Harvard and MIT. He is a prolific researcher studying genetic sequencing, genome editing, ...

John F. Crowley is president and CEO of the Biotechnology Innovation Organization. Kendalle Burlin O’Connell is CEO and president of MassBio. As nearly 20,000 scientists, executives, investors, ...

In an effort to battle against what members feel is an existential threat to their business, a group of 10 domestic biotech companies have launched the Midsized Biotech Alliance of America with a ...

From Philly and the Pa. suburbs to South Jersey and Delaware, what would you like WHYY News to cover? Let us know! Philadelphia’s biotechnology industry is facing a wave of uncertainty, as several ...

The Biotech industry has underperformed due to the Trump administration, RFK Jr.'s skepticism, and funding uncertainty, with major ETFs down 19-25% over six months. Some biotech companies with ...